COX2 Inhibitor Market: Competitive Landscape, Pipeline, and Market Analysis 2023

Purchase Option

$ 4400
$ 6600
$ 8900

COX2 inhibitors are a class of drugs that selectively inhibit the enzyme cyclooxygenase-2 (COX-2), which is responsible for producing prostaglandins involved in inflammation and pain. By targeting COX-2, these inhibitors reduce inflammation and provide pain relief. They are primarily used in the treatment of various inflammatory conditions, such as rheumatoid arthritis, feline osteoarthritis, and acute pain. COX2 inhibitors differ from non-selective nonsteroidal anti-inflammatory drugs (NSAIDs) by specifically targeting the COX-2 enzyme while sparing COX-1, which is responsible for maintaining normal physiological functions like protecting the stomach lining. According to WHO, rheumatoid arthritis affects approximately 1% of the global population, with higher prevalence rates in Europe and the United States. In Europe, the estimated prevalence of rheumatoid arthritis is around 0.5-1%, affecting millions of individuals. In the United States, around 1.3 million adults have been diagnosed with rheumatoid arthritis. Additionally, osteoarthritis is a leading cause of joint pain and disability globally, affecting millions of people. In Europe, around 10% of the population is affected by osteoarthritis, while in the United States, more than 32 million adults have osteoarthritis.

The growth drivers of the COX2 inhibitor market include the increasing prevalence of inflammatory conditions, such as rheumatoid arthritis and osteoarthritis, globally. The rising aging population, coupled with a sedentary lifestyle and obesity, contributes to the higher incidence of these conditions. Additionally, the demand for effective pain management options and the growing acceptance of COX2 inhibitors as a safer alternative to traditional NSAIDs drive market growth. Furthermore, continuous research and development efforts to improve the safety profile and efficacy of COX2 inhibitors are also key factors driving market expansion. Companies such as Novartis, AbbVie, Bayer, Jiangsu Hengrui Pharma, Achelios Therapy, Adastra Pharma, Allodynic, Antibe, Aptys Pharma, Axsome Therapy, Baudax Bio, Burke Therapy, Cadila, Celtic, Ceska Lekarnicka, Coeptis, Collegium Pharma, CrystalGenomics, Daewoong Pharma, Dr. Reddy's cater to this category. Moreover, many companies are coming up with new molecules in this space. For instance, GSK is one such company that is currently conducting a clinical trial of the drug GW406381 for the treatment of arthritis.

Key Developments

  • In January 2023, Harrow health closed the acquisition of US commercial rights of Nepafenac from Novartis
  • In June 2022, Tremeau Pharmaceuticals got patent protection for Rofecoxib in the US

Approved COX2 Inhibitor molecules

  • Consensi (amlodipine, celecoxib)
  • Metapain (nefopam, paracetamol)
  • Celecoxib, diacerein
  • Delivra-celecoxib cream
  • Diclofenac, eperisone
  • Diclofenac, misoprostol
  • Etoricoxib, tramadol
  • Naproxen delayed-release
  • Oxycodone hydrochloride, aspirin
  • Paracetamol Uniflash
  • Loqoa Tape (esflurbiprofen transdermal)
  • Ocufen (flurbiprofen ophthalmic solution)
  • Tolfenamic acid

COX2 Inhibitor Pipeline Molecules

  • CA102N
  • E-58425
  • Celecoxib, famciclovir (IMC-1)
  • Celecoxib, tramadol (YYC301)
  • Imrecoxib, tramadol (HR18042)
  • Indometacin, L-menthol (K-285)
  • Ketoprofen (TDT 070)
  • ECP-1014
  • SRP-001
  • Topofen (ketoprofen topical gel 2%)
  • Ibuprofen topical (TIB200)
  • Indomethacin, levonorgestrel (BAY98-7443)
  • Mefenamic acid (PSD508)
  • Methyl salicylate and menthol (SPR300)

Clinical Activity and Development of COX2 Inhibitor

In the COX2 Inhibitor space, more than 66 companies are conducting more than 200 clinical trials in this category of drugs. For instance,

  • In March 2023, US FDA assigned a PDUFA action date of (23/10/2023) for bupivacaine/meloxicam sNDA for Postoperative pain
  • In March 2023, US FDA accepted sNDA for bupivacaine/meloxicam for postoperative pain in soft tissue and orthopedic surgical procedures in USA for review

Product Name

Total Studies





Celecoxib, famciclovir (IMC-1)


Celecoxib, tramadol (YYC301)


Imrecoxib, tramadol (HR18042)


Indometacin, L-menthol (K-285)


Ketoprofen (TDT 070)






Topofen (ketoprofen topical gel 2%)


Ibuprofen topical (TIB200)


Indomethacin, levonorgestrel (BAY98-7443)


Mefenamic acid (PSD508)


Methyl salicylate and menthol (SPR300)



Target Indication Analysis of COX2 Inhibitor

COX2 inhibitors are primarily targeted for the treatment of inflammatory conditions, specifically rheumatoid arthritis and osteoarthritis. Rheumatoid arthritis is a chronic autoimmune disorder characterized by inflammation in the joints, leading to pain, stiffness, and joint damage. COX2 inhibitors help reduce inflammation and manage pain in individuals with rheumatoid arthritis. Osteoarthritis, on the other hand, is a degenerative joint disease that results from wear and tear of the joints. COX2 inhibitors are used to alleviate pain and inflammation associated with osteoarthritis, improving the quality of life for affected individuals. By targeting the underlying inflammation, COX2 inhibitors provide relief from symptoms and help manage these chronic conditions.

Frequently Asked Questions

COX2 inhibitors drugs are used in the management of inflammatory conditions, specifically rheumatoid arthritis and osteoarthritis.

The market is primarily driven by factors such as the rising incidence of inflammatory conditions, particularly rheumatoid arthritis and osteoarthritis, which fuels the demand for effective pain management options. The aging population and the rising burden of chronic pain contribute to this demand.

The major players in this space are Novartis, AbbVie, Bayer, Jiangsu Hengrui Pharma, Achelios Therap, Adastra Pharma, Allodynic, Antibe, Aptys Pharma, Axsome Therap, Baudax Bio, Burke Therap, Cadila, Celtic, Ceska Lekarnicka, Coeptis, Collegium Pharma, CrystalGenomics, Daewoong Pharma, Dr. Reddy's.

Despite favorable market conditions, the COX2 Inhibitor drug market faces certain restraints. One major challenge is the high cost of COX2 Inhibitor inhibitors, which can limit access for patients and strain healthcare budgets. Additionally, the potential side effects and toxicity associated with COX2 Inhibitor inhibitors pose concerns for both patients and healthcare providers, requiring careful monitoring and management during treatment.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • Novartis
  • AbbVie
  • Bayer
  • Jiangsu Hengrui Pharma
  • Achelios Therap
  • Adastra Pharma
  • Allodynic
  • Antibe
  • Aptys Pharma
  • Axsome Therap
  • Baudax Bio
  • Burke Therap
  • Cadila
  • Celtic
  • Ceska Lekarnicka
  • Coeptis
  • Collegium Pharma
  • CrystalGenomics
  • Daewoong Pharma
  • Reddy’s
  • ENovate Biolife
  • Esteve
  • Euclises Pharma
  • GC Biopharma
  • GSK
  • Guangzhou Xiangxue Pharma
  • Harvest One Cannabis
  • Heron Therapeutics
  • Hisamitsu
  • Holy Stone Healthcare
  • Iroko
  • Kowa
  • Kyowa Kirin
  • LG Chem
  • Laboratorios Silanes
  • Menarini
  • Miravo
  • Mundipharma
  • NeuroSense Therap
  • Nicox
  • Nogra Pharma
  • Nuance Biotech
  • Old API Wind-down
  • Omeros
  • Ono Pharma
  • Pfizer
  • Purdue
  • Purple Biotech
  • Reata
  • Regent Pacific Group
  • Simcere
  • Sirnaomics
  • Sorrento
  • South Rampart Pharma
  • Sun Pharma
  • Taisho
  • Takeda
  • Tremeau Pharma
  • Unither
  • Vicus
  • Virios Therap
  • Yooyoung Pharma
  • Yuhan Corp
  • e-therap

Adjacent Markets